|
|
Volumn 163, Issue 10, 2003, Pages 1243-1244
|
|
Is low-molecular-weight heparin safer than warfarin for secondary prevention of venous thromboembolism in cancer patients? [12] (multiple letters)
a a a a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTICOAGULANT AGENT;
HEPARIN;
LOW MOLECULAR WEIGHT HEPARIN;
WARFARIN;
BLEEDING;
BONE DEMINERALIZATION;
BONE DENSITY;
CANCER PATIENT;
DRUG EFFICACY;
DRUG SAFETY;
FRACTURE;
HUMAN;
LETTER;
LONG TERM CARE;
OSTEOPOROSIS;
PRIORITY JOURNAL;
RISK BENEFIT ANALYSIS;
SIDE EFFECT;
THROMBOCYTOPENIA;
THROMBOEMBOLISM;
THROMBOSIS;
VEIN THROMBOSIS;
ADULT;
AGED;
AGED, 80 AND OVER;
ANTICOAGULANTS;
DOSE-RESPONSE RELATIONSHIP, DRUG;
EMBOLISM;
ENDPOINT DETERMINATION;
FEMALE;
HEMORRHAGE;
HEPARIN, LOW-MOLECULAR-WEIGHT;
HUMANS;
INTERNATIONAL NORMALIZED RATIO;
MALE;
MIDDLE AGED;
NEOPLASMS;
RANDOMIZED CONTROLLED TRIALS;
RECURRENCE;
SURVIVAL ANALYSIS;
TREATMENT OUTCOME;
VENOUS THROMBOSIS;
WARFARIN;
|
|
EID: 0037568114
PISSN: 00039926
EISSN: None
Source Type: Journal
DOI: 10.1001/archinte.163.10.1243-a Document Type: Letter |
|
Times cited : (4)
|
|
References (0)
|